2 completed, 1 active not recruiting, 1 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Actinomycin D: new trials by email Literature Review of Actinomycin D trials Research Report on Actinomycin D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evolutionary Therapy for Rhabdomyosarcoma Vincristine, Cyclophosphamide, Vinorelbine - Rhabdomyosarcoma | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2020-12-29 | 2025-11-26 |
| FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma Irinotecan, Actinomycin D, Doxorubicin - Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Birmingham | 1672 | 2020-09-17 | 2024-05-23 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 175 | 2010-01-01 | 2017-08-29 |
| Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT filgrastim, cisplatin, cyclophosphamide - Central Nervous System Tumor, Pediatric | Phase 2 | Completed | Dana-Farber Cancer Institute | 25 | 2003-02-01 | 2015-12-24 |
Rhabdomyosarcoma (3) · Sarcoma (2) · Central Nervous System Neoplasms (1) · Rhabdoid Tumor (1)
Dana-Farber Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Cancer Institute (NCI) (1) · University of Birmingham (1)
United States (3) · Australia (2) · New Zealand (2) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1) · Ireland (1) · Israel (1) · Italy (1) · Netherlands (1) · Norway (1)
Jonathan Metts, MD (1) · Mark W. Kieran, MD, PhD (1) · Meriel Jenney (1) · Suman Malempati, MD (1)
2018 (1), P30CA006516 (1), U10CA098543 (1), U10CA180886 (1)